USP9X and cholangiocarcinoma: Comprehensive validation using clinical samples, cell lines, and animal models has established USP9X as a potential prognostic biomarker and therapeutic target for cholangiocarcinoma, challenging the previous notion of USP9X as solely an oncogenic factor and providing both a theoretical basis and new translational directions for precision diagnosis and treatment of this malignancy.